Skip to main content
SpringerLink
Log in

Oral Etoposide for the Treatment of Recurrent Ovarian Cancer

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral etoposide has been studied in numerous clinical trials for the treatment of recurrent ovarian cancer. In different studies there has been a varied response rate, and it appears that the activity of this drug is dependent to a large part on the extent of prior therapy. On the basis of data from more than 270 patients in 9 different studies, the overall response rate is 20.4%. However, in the largest study performed by the Gynecologic Oncology Group (GOG), in which 82 previously treated patients received oral etoposide, the response rate was 30.5%. The GOG study categorised patients who received oral etoposide according to their response to initial therapy: patients were deemed either platinum sensitive or platinum resistant. No patients had received more than one prior regimen at the time they were entered into the oral etoposide trial. In 41 platinum-resistant patients, the overall response rate was 26.8%, including a 7.3% clinical complete remission rate. In patients who were platinum sensitive, the overall response rate was 34.1%, with a 14.6% clinical complete remission rate. Toxicity was acceptable, with myelosuppression being the dose-limiting toxicity. This GOG study confirms the activity of oral etoposide as second-line therapy both for platinum-resistant and platinum-sensitive ovarian cancer patients. Additional studies are in progress to determine how oral etoposide can be combined with paclitaxel and a platinum compound for use as initial therapy for previously untreated patients with advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology 1997; 11: 95–105

    PubMed  CAS  Google Scholar 

  2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  3. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998; 17: 361A

    Google Scholar 

  4. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895–902

    PubMed  CAS  Google Scholar 

  5. Ozols RF. Treatment of recurrent ovarian cancer: increasing options-‘Recurrent’ results [editorial]. J Clin Oncol 1997; 15: 2177–80

    PubMed  CAS  Google Scholar 

  6. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–93

    PubMed  CAS  Google Scholar 

  7. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pre-treated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963–8

    Article  PubMed  CAS  Google Scholar 

  8. Markman M. Prognostic factors in salvage therapy of ovarian cancer [editorial]. Ann Oncol 1997; 8: 937–8

    Article  PubMed  CAS  Google Scholar 

  9. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584–8

    PubMed  CAS  Google Scholar 

  10. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187–92

    PubMed  CAS  Google Scholar 

  11. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93

    PubMed  Google Scholar 

  12. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552–7

    PubMed  CAS  Google Scholar 

  13. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530–3

    Article  PubMed  CAS  Google Scholar 

  14. Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676–81

    Article  PubMed  CAS  Google Scholar 

  15. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–93

    PubMed  CAS  Google Scholar 

  16. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269–71

    CAS  Google Scholar 

  17. Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47: 282–6

    Article  PubMed  CAS  Google Scholar 

  18. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243–8

    PubMed  CAS  Google Scholar 

  19. Edmonson JH, Decker DG, Malkasian GD, et al. Phase II evaluation of VP-16-213 (NS C-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol 1978; 6: 7–9

    Article  PubMed  CAS  Google Scholar 

  20. Slayton RE, Creasman WT, Petty W, et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63: 2089–92

    PubMed  CAS  Google Scholar 

  21. Maskens AP, Armand JP, Lacave AJ, et al. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 1981; 65: 329–30

    PubMed  CAS  Google Scholar 

  22. Greco FA. Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 1993; 19 Suppl. C: 35–45

    Article  PubMed  Google Scholar 

  23. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinomas: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405–10

    PubMed  CAS  Google Scholar 

  24. Markman M, Hakes T, Reichman B, et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992; 119: 55–7

    Article  PubMed  CAS  Google Scholar 

  25. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191–5

    Article  PubMed  CAS  Google Scholar 

  26. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60–3

    PubMed  CAS  Google Scholar 

  27. Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. Gynecol Oncol 1990; 36: 369–70

    Article  PubMed  CAS  Google Scholar 

  28. Kavanagh JJ, Tresukosol D, Gonzalez De Leon C, et al. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 1995; 5: 351–4

    Article  PubMed  Google Scholar 

  29. de Wit R, van der Burg ME, van den Gaast A, et al. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656–7

    PubMed  Google Scholar 

  30. Marzola M, Zucchetti M, Colombo N, et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4: 517–9

    PubMed  CAS  Google Scholar 

  31. Garrow GC, Hainsworth JD, Johnson DH, et al. Prolonged administration of oral etoposide in previously-treated epithelial ovarian cancer: a phase II trial. Proc Am Soc Clin Oncol 1992; 11: 236A

    Google Scholar 

  32. de Jong RS, Hofstra LS, Willemse PH, et al. Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1997; 66: 197–201

    Article  PubMed  Google Scholar 

  33. van der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5: 301–5

    Article  Google Scholar 

  34. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer. A Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998; 69: 226–9

    CAS  Google Scholar 

  35. Thigpen JT. Dose-intensity in ovarian carcinoma: hold, enough? J Clin Oncol 1997; 15: 1291–3

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania, 19111, USA

    Robert F. Ozols

Authors
  1. Robert F. Ozols
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozols, R.F. Oral Etoposide for the Treatment of Recurrent Ovarian Cancer. Drugs 58 (Suppl 3), 43–49 (1999). https://doi.org/10.2165/00003495-199958003-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00007

Keywords

Search

Navigation